Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Successful targeting of the NRG1 fusion reveals durable response to afatinib in lung adenocarcinoma: a case report

1 Oct 2021

Abstract excerpt

Abstract: The treatments for advanced non-small cell lung cancer (NSCLC) patients have been improved by developing tyrosine kinase inhibitors (TKIs) as targeted therapies. Oncogenic gene fusions resulting from structural DNA rearrangements have been proposed as a unique class of oncogenic drivers and therapeutic targets. Currently approved TKIs mainly focused on a few well-known fusion genes such as anaplastic...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cancer-related gene regulation
Share to Lung Cancer Treatments and Mutations
Share to Peptidase Inhibition and Analysis

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 34805369
DOI: 10.21037/atm-21-3923

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Successful targeting of the NRG1 fusion reveals durable response to afatinib in lung adenocarcinoma: a case reportPMID 34805369Read ↗

A case of multiple primary lung adenocarcinoma with a CD74-NRG1 fusion protein and HER2 mutation benefit from combined target therapy.Semantic proximity Read ↗

NRG1 Gene Fusions—What Promise Remains Behind These Rare Genetic Alterations? A Comprehensive Review of Biology, Diagnostic Approaches, and Clinical ImplicationsSemantic proximity Read ↗

Therapeutic Potential of Afatinib in NRG1 Fusion-Driven Solid Tumors: A Case Series.Semantic proximity Read ↗

Characterizing the molecular and clinical implications of NRG1 fusions in NSCLC through integrated RNA and DNA sequencing analysis.Semantic proximity Read ↗

Expert Consensus on the Diagnosis and Treatment of NRG1/2 Gene Fusion Solid TumorsSemantic proximity Read ↗

NRG1 Gene Fusions Are Recurrent, Clinically Actionable Gene Rearrangements in KRAS Wild-Type Pancreatic Ductal AdenocarcinomaSemantic proximity Read ↗

<i>CD74–NRG1</i> Fusions in Lung AdenocarcinomaSemantic proximity Read ↗

Neuregulin 1 Gene (NRG1). A Potentially New Targetable Alteration for the Treatment of Lung CancerSemantic proximity Read ↗

Detection of NRG1 Gene Fusions in Solid TumorsSemantic proximity Read ↗

A Novel KIF5B-EGFR Fusion Variant in Non-Small-Cell Lung Cancer and Response to Afatinib: A Case ReportSemantic proximity Read ↗

Emerging oncogenic fusions other than ALK, ROS1, RET, and NTRK in NSCLC and the role of fusions as resistance mechanisms to targeted therapySemantic proximity Read ↗

RNA Sequencing Identifies Novel NRG1 Fusions in Solid Tumors that Lack Co-Occurring Oncogenic DriversSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.